Sugi Predict

Sugi Predict / Compounds / SCHEMBL1192999

SCHEMBL1192999

SCHEMBL1192999

CCSc1cc(N)c([N+](=O)[O-])cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ PDE7A Q13946 4/20 0.44
▸ LMNA P02545 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ TDP1 Q9NUW8 4/20 0.42
▸ TSHR P16473 3/20 0.42
▸ CYP3A4 P08684 2/20 0.41
▸ SLC6A4 P31645 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ MAPK1 P28482 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1192600 0.88 MAPT (0.44) MAPTALDH1A1PDE7ALMNAMEN1
SCHEMBL8350990 0.85 MAPT (0.44) MAPTALDH1A1PDE7ALMNAMEN1
SCHEMBL6949538 0.83 MAPT (0.50) MAPTALDH1A1PDE7ALMNAMEN1
SCHEMBL22557347 0.81 ALDH1A1 (0.41) MAPTALDH1A1LMNATSHRCYP3A4
SCHEMBL15358170 0.80 PDE7A (0.49) MAPTALDH1A1PDE7ALMNATSHR
SCHEMBL20535310 0.79 NPC1 (0.49) MAPTALDH1A1PDE7ALMNAMEN1
SCHEMBL1193378 0.79 PDE7A (0.49) MAPTALDH1A1PDE7AMEN1KMT2A
SCHEMBL1192794 0.78 MAPT (0.46) MAPTALDH1A1PDE7ALMNAMEN1
SCHEMBL17897801 0.78 LMNA (0.44) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL6974220 0.76 MAPT (0.47) MAPTALDH1A1PDE7ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2023-04-04 — — US disclosed
US-20210078978-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-03-18 — — US disclosed
US-10851083-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2020-12-01 — — US disclosed
US-20180215732-A9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-08-02 — — US disclosed
US-20180022733-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-01-25 — — US disclosed
US-20160168127-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-06-16 — — US disclosed
US-9073923-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-07-07 — — US disclosed
EP-2294066-B9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-03-11 — — EP disclosed
US-8865713-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-10-21 — — US disclosed
US-20140256722-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-11 — — US disclosed
EP-2294066-B1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-13 — — EP disclosed
US-8759345-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 — — US disclosed
US-20140005193-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (US) 2014-01-02 — — US disclosed
EP-2294066-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2011-03-16 — — EP disclosed
US-20110046132-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-02-24 — — US disclosed
WO-2009134750-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-11-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors P4HA1, PAH, EGLN3 MAPT 2583/4885ALDH1A1 46/4885PDE7A 1465/4885
US-20110046132-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2687/4885ALDH1A1 32/4885PDE7A 1598/4885
US-20180022733-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2583/4885ALDH1A1 46/4885PDE7A 1465/4885
US-20140005193-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2583/4885ALDH1A1 46/4885PDE7A 1465/4885
US-10851083-B2 Benzoimidazoles as prolyl hydroxylase inhibitors P4HA1, PAH, EGLN3 MAPT 2583/4885ALDH1A1 46/4885PDE7A 1465/4885
US-20180215732-A9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2583/4885ALDH1A1 46/4885PDE7A 1465/4885
US-20140256722-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2583/4885ALDH1A1 46/4885PDE7A 1465/4885
US-20210078978-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2583/4885ALDH1A1 46/4885PDE7A 1465/4885
US-20160168127-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2583/4885ALDH1A1 46/4885PDE7A 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.